![MMAE-[d8]](https://resource.bocsci.com/structure/2070009-72-0.gif)
Inquiry Basket
CAS No.: 2227102-46-5
Cat No.: BADC-01609
4.5 
Patritumab deruxtecan is an antibody-drug conjugate consisting of a human anti-HER3 monoclonal antibody conjugated to a topoisomerase I inhibitor payload via a stable tetrapeptide-based cleavable linker.
Structure of 2227102-46-5
* For research and manufacturing use only. We do not sell to patients.
| Size | Price | Stock | Quantity |
|---|---|---|---|
| -- | $-- | In stock |
Looking for different specifications? Click to request a custom quote!
Capabilities & Facilities
Popular Publications Citing BOC Sciences Products
| Catalog | Product Name | CAS | Inquiry |
|---|---|---|---|
| BADC-00606 | Deruxtecan | 1599440-13-7 | |
| BADC-01602 | Trastuzumab deruxtecan | 1826843-81-5 | |
| BADC-01595 | Datopotamab deruxtecan | 2238831-60-0 |
Patritumab deruxtecan
Required fields are marked with *
Patritumab deruxtecan
Required fields are marked with *
Contact our experts today for pricing and comprehensive details on our ADC offerings.
From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.
Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.
Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.
